Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05812963
Other study ID # FRAMEAMI119023
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 18, 2023
Est. completion date December 31, 2029

Study information

Verified date November 2023
Source Samsung Medical Center
Contact Joo Myung Lee, MD, MPH, PhD
Phone 82-2-3410-2575
Email drone80@hanmail.net
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to compare clinical outcomes between intravascular ultrasound (IVUS)-guided treatment decision versus fractional flow reserve (FFR)-guided treatment decision for non-infarct related artery stenosis in patients with ST-segment elevation MI (STEMI) and multivessel disease.


Description:

The treatment of choice of ST-segment elevation myocardial infarction (STEMI) is acute reperfusion therapy, preferably with primary percutaneous coronary intervention (PCI). While need of treating the infarct related artery (IRA) is obvious, need for routine revascularization of non-infarct related artery (non-IRA) has been a topic of debate until recent years. Through a number of observational studies, randomized trials and meta-analyses, the benefits of non-IRA PCI have been continuously implied, and COMPLETE trial with 4041 patients of STEMI and multivessel coronary artery disease in 2019 demonstrated superiority of complete revascularization to culprit-only PCI in terms of cardiovascular death or MI (primary end point) and cardiovascular death, MI, or ischemia-driven revascularization (co-primary end point).8 As such, complete revascularization of a significant non-IRA stenosis is recommended after successful primary PCI in STEMI patients in current clinical guidelines. Nevertheless, it has been unclear which criteria should be used to decide non-IRA PCI. Although potential significance of non-IRA lesions can be estimated by angiography, the limitation of angiographic visual assessment or quantitative coronary angiography has been well known. Various measurements are used for incremental information in addition to angiographic assessment in guiding PCI - namely, intravascular ultrasound (IVUS) and fractional flow reserve (FFR). IVUS provides anatomical information regarding the lumen, plaque, and plaque characteristics, and can optimize stent placement minimizing stent-related problems and lead to better clinical outcomes. On the other hand, FFR provides information on amount of ischemia which the stenosis in question is causing, and also improves the quality of PCI which has been demonstrated by multiple previous trials, and current practice guidelines recommend the use of FFR to determine revascularization strategy as Class IA recommendation. Recent trials evaluated comparative prognosis between FFR-guided versus angiograph-guided PCI for non-IRA in patients with acute MI and multivessel disease. FLOWER-MI trial showed comparable clinical outcome between FFR-guided versus angiography-guided PCI for non-IRA in STEMI patients at 1-year follow-up. FRAME-AMI trial showed superiority of FFR-guided PCI over angiography-guided PCI in reducing death, MI, or repeat revascularization during median 3.5 years of follow-up. Although IVUS and FFR differ in underlying basic concepts, previous studies demonstrated clinical outcomes following treatment decision by IVUS and FFR was similar between the 2 groups. However, these studies mainly evaluated low-risk stable ischemic heart disease patients with intermediate stenosis, and does not reflect population with acute myocardial infarction undergoing complete revascularization. Currently, the data directly comparing the benefit of IVUS and FFR for non-IRA PCI in STEMI is lacking. Considering that coronary atherosclerotic plaque in non-IRA of STEMI patients is associated with significantly higher risk of future clinical events, IVUS would have potential strength of detecting high risk plaque in non-IRA and treatment decision based on plaque characteristics. Conversely, FFR-guided treatment decision for non-IRA would detect functionally significant non-IRA stenosis and treatment decision based on functional significance would reduce unnecessary PCI, as demonstrated by previous trials. In this regard, randomized controlled trial comparing clinical outcome following non-IRA PCI in STEMI patients with multivessel disease guided by IVUS or FFR would provide valuable evidence to enhance patient's prognosis after treatment of STEMI. Therefore, FRAME-AMI 2 trial is designed to compare clinical outcomes after non-IRA PCI using either IVUS-guided or FFR-guided strategy.


Recruitment information / eligibility

Status Recruiting
Enrollment 1400
Est. completion date December 31, 2029
Est. primary completion date December 31, 2028
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: - Subject must be at least 19 years of age - Acute ST-segment elevation myocardial infarction (STEMI) *STEMI: ST-segment elevation =0.1 mV in =2 contiguous leads or documented newly developed left bundle-branch block1 - Successful primary percutaneous coronary intervention (PCI) for IRA in <12 h after the onset of symptoms - Multivessel disease (at least one stenosis of >50% in a non-IRA =2.25 mm by visual estimation) - Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic evaluation and PCI and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure. Exclusion Criteria: - Non-IRA stenosis not amenable for PCI treatment by operators' decision - Cardiogenic shock (Killip class IV) already at presentation or the completion of IRA PCI - Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus - Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock) - Pregnancy or breast feeding - Non-cardiac co-morbid conditions are present with life expectancy <2 year or that may result in protocol non-compliance (per site investigator's medical judgment) - Other primary valvular disease with severe degree: severe mitral regurgitation, mitral stenosis, severe aortic regurgitation, or aortic stenosis - Unwillingness or inability to comply with the procedures described in this protocol.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
IVUS-guided PCI group
In IVUS-guided PCI group, the current trial evaluates clinical outcome following IVUS-guided treatment decision for revascularization of non-IRA stenosis.
FFR-guided PCI group
In FFR-guided PCI group, FFR measurement for non-IRA stenosis (>50% visual estimation) will be performed by continuous infusion of adenosine (140~180 ug/kg/min) or intracoronary nicorandil (2 mg bolus) injection. The FFR =0.80 will be targeted for PCI. In case of non-IRA stenosis >90%, we will judge FFR value of =0.80.

Locations

Country Name City State
Korea, Republic of Chonnam National University Gwangju
Korea, Republic of Samsung Medical Center Seoul

Sponsors (2)

Lead Sponsor Collaborator
Samsung Medical Center Chonnam National University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patient-Oriented Composite Outcome a composite of death, myocardial infarction, or repeat revascularization 2 years after last patient enrollment
Secondary All-cause death All-cause death 2 years after last patient enrollment
Secondary Cardiac death Cardiac death 2 years after last patient enrollment
Secondary Spontaneous myocardial infarction Spontaneous myocardial infarction, defined by Forth Universal definition of myocardial infarction 2 years after last patient enrollment
Secondary Procedure-related myocardial infarction Procedure-related myocardial infarction, defined by ARC II definition 2 years after last patient enrollment
Secondary Any revascularization Any revascularization (clinically-driven or ischemia-driven) 2 years after last patient enrollment
Secondary Infarct-related artery revascularization Infarct-related artery revascularization 2 years after last patient enrollment
Secondary Non-Infarct-related artery revascularization Non-Infarct-related artery revascularization 2 years after last patient enrollment
Secondary Definite or probable stent thrombosis Definite or probable stent thrombosis 2 years after last patient enrollment
Secondary Stroke (ischemic or hemorrhagic) Stroke (ischemic or hemorrhagic) 2 years after last patient enrollment
Secondary Total procedural time Total procedural time (from the end of primary PCI for IRA to the completion of non-IRA PCI including amount of staged procedure) at least 1 week after index procedure
Secondary Total fluoroscopy time Total fluoroscopy time (from the end of primary PCI for IRA to the completion of non-IRA PCI including amount of staged procedure) at least 1 week after index procedure
Secondary Total amount of contrast use Total amount of contrast use (from the end of primary PCI for IRA to the completion of non-IRA PCI including amount of staged procedure) at least 1 week after index procedure
Secondary Incidence of contrast-induced nephropathy Incidence of contrast-induced nephropathy, defined as an increase in serum creatinine of =0.5mg/dL or =25% from baseline within 48-72 hours after contrast agent exposure. at least 1 week after index procedure
Secondary A composite of all-cause death or myocardial infarction A composite of all-cause death or myocardial infarction 2 years after last patient enrollment
Secondary A composite of cardiac death or non-procedure-related myocardial infarction A composite of cardiac death or non-procedure-related myocardial infarction 2 years after last patient enrollment
Secondary Angina severity by Seattle Angina Questionnaire Angina severity by Seattle Angina Questionnaire At 2 years from index procedure
Secondary Quality of life by EQ-5D-5L Questionnaire Quality of life by EQ-5D-5L Questionnaire At 2 years from index procedure
See also
  Status Clinical Trial Phase
Recruiting NCT05601999 - Study of Efficacy and Safety of GNR-060 vs Metalyse in Patients With ST Elevation Myocardial Infarction Phase 3
Recruiting NCT06147986 - Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells as an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients Phase 2
Not yet recruiting NCT05881382 - Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction Phase 3
Enrolling by invitation NCT02615015 - SNPs in the DNase 1 Gene Impair Its Activity and Are Increased in a STE-ACS Patient Cohort Compared to Healthy Controls N/A
Recruiting NCT05554588 - Intrathrombus Thrombolysis Versus Aspiration Thrombectomy During Primary PCI N/A
Recruiting NCT05450757 - Shanghai ST-segment Elevation Myocardial Infarction Cohort
Active, not recruiting NCT03278509 - Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART) Phase 4
Completed NCT03156699 - The Incidence, Effect and Persistence of Fragmented-QRS, in Patients Presenting With ST-Elevation Myocardial Infarction
Not yet recruiting NCT03266328 - Procedure and In-hospital Outcome of Patients Under 40 Years Old Undergoing Primary Percutaneous Coronary Intervention for Acute ST Elevated Myocardial Infarction in Assiut University N/A
Not yet recruiting NCT03263468 - Revascularization StrategIes for ST Elevation Myocardial Infarction Trial N/A
Not yet recruiting NCT05605288 - Distal Versus Conventional Transradial Artery Access for Coronary Catheterization in Patients With STEMI N/A
Enrolling by invitation NCT04970238 - Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction Phase 4
Recruiting NCT02557217 - NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction Phase 2
Recruiting NCT02224534 - Ticagrelor Versus Clopidogrel in Left Ventricular Remodeling After ST-segment Elevation Myocardial Infarction Phase 4
Completed NCT01136187 - Trial Comparing Radial and Femoral Approach in Primary Percutaneous Coronary Intervention (PCI) N/A
Not yet recruiting NCT04068116 - Impact of Ischemic Post-conditioning N/A
Not yet recruiting NCT04063345 - Long-term Clinical Outcomes of intraVascular Ultrasound-guided vs Angiography-guided Primary pErcutaneous Intervention in Patients With Acute ST Segment Elevated Myocardial Infarction Phase 2/Phase 3
Active, not recruiting NCT03646357 - BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic Function Phase 4
Completed NCT03984071 - The Predictive Value of eGFR for Adverse Cardiovascular Events in Patients With STEMI
Completed NCT03740776 - The Eosinophils Percentage Predicts In-hospital Major Adverse Cardiac Events in STEMI Patients After PCI